ZIMLAB

Zim Laboratories Share Price

₹110.95 -0.35 (-0.31%)

28 Dec, 2024 02:34

SIP TrendupStart SIP in ZIMLAB

Start SIP

Performance

  • Low
  • ₹109
  • High
  • ₹112
  • 52 Week Low
  • ₹90
  • 52 Week High
  • ₹131
  • Open Price₹112
  • Previous Close₹111
  • Volume31,285

Investment Returns

  • Over 1 Month + 0.63%
  • Over 3 Month + 4.52%
  • Over 6 Month + 5.67%
  • Over 1 Year -3.31%
SIP Lightning

Smart Investing Starts Here Start SIP with Zim Laboratories for Steady Growth!

Invest Now

Zim Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 33.5
  • PEG Ratio
  • -3
  • Market Cap Cr
  • 541
  • P/B Ratio
  • 2.3
  • Average True Range
  • 4.23
  • EPS
  • 3.31
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.64
  • RSI
  • 45.52
  • MFI
  • 13.6

Zim Laboratories Financials

Zim Laboratories Technicals

EMA & SMA

Current Price
₹110.95
-0.35 (-0.31%)
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹112.01
  • 50 Day
  • ₹111.22
  • 100 Day
  • ₹110.67
  • 200 Day
  • ₹110.05

Resistance and Support

110.18 Pivot Speed
  • R3 113.92
  • R2 112.83
  • R1 111.27
  • S1 108.62
  • S2 107.53
  • S3 105.97

What's your outlook on Zim Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Zim Laboratories has an operating revenue of Rs. 388.12 Cr. on a trailing 12-month basis. An annual revenue de-growth of -8% needs improvement, Pre-tax margin of 6% is okay, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 15%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its key moving averages, around 1% and 2% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 13% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 79 which is a FAIR score but needs to improve its earnings, a RS Rating of 46 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Zim Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-09 Quarterly Results
2024-08-03 Quarterly Results
2024-05-13 Audited Results
2024-01-29 Quarterly Results
2023-11-01 Quarterly Results
Date Purpose Remarks
2022-12-22 Bonus Rs.0.00 issue in the ratio of 2:1 of Rs. 10/-

Zim Laboratories F&O

Zim Laboratories Shareholding Pattern

33.26%
0%
45.48%
21.26%

About Zim Laboratories

  • NSE Symbol
  • ZIMLAB
  • BSE Symbol
  • 541400
  • Chairman & Managing Director
  • Dr. Anwar Daud
  • ISIN
  • INE518E01015

Similar Stocks to Zim Laboratories

Zim Laboratories FAQs

Zim Laboratories share price is ₹110 As on 28 December, 2024 | 02:20

The Market Cap of Zim Laboratories is ₹540.6 Cr As on 28 December, 2024 | 02:20

The P/E ratio of Zim Laboratories is 33.5 As on 28 December, 2024 | 02:20

The PB ratio of Zim Laboratories is 2.3 As on 28 December, 2024 | 02:20

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23